N-CADHÉRINE ET FGFR1 ET/OU FGFR4 DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉDICTION DE LA RÉPONSE DES PATIENTS À UN TRAITEMENT DU CANCER DU POUMON ET PROCÉDÉ ET KIT BASÉS SUR LADITE UTILISATION
Fundación De Investigación Hospital 12 De Octubre;Servicio Andaluz de Salud;Consejo Superior de Investigaciones Científicas (CSIC)
发明人:
申请号：
EP18836033.3
公开号：
EP3636773A1
申请日:
2018.07.13
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention describes a method for predicting the response of a subject suffering from lung cancer to treatment with FGFR inhibitors. The relationship between the expression of the biomarkers and the treatment response allows the subjects to be classified as responsive or unresponsive to the treatment, which facilitates the therapeutic decision-making of the attending clinician. The present invention also describes the biomarkers N-cadherin, FGFR1 and FGFR4, how to analyse them and how to interpret the results obtained, in order to administer FGFR inhibitors only to the subjects that are responsive to the treatment, thereby optimising the same, which allows the unresponsive subjects to be treated with alternative therapies to the FGFR inhibitors.
